ES2444299B1 - Uso de un hidrolizado de caseina como agente antiherpético - Google Patents

Uso de un hidrolizado de caseina como agente antiherpético Download PDF

Info

Publication number
ES2444299B1
ES2444299B1 ES201231324A ES201231324A ES2444299B1 ES 2444299 B1 ES2444299 B1 ES 2444299B1 ES 201231324 A ES201231324 A ES 201231324A ES 201231324 A ES201231324 A ES 201231324A ES 2444299 B1 ES2444299 B1 ES 2444299B1
Authority
ES
Spain
Prior art keywords
casein hydrolyzate
antiherpetic agent
antiherpetic
agent
hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201231324A
Other languages
English (en)
Other versions
ES2444299A1 (es
Inventor
Guillermo LÓPEZ ZARCO
Pere ADELL WINKLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTD Labs SL
Original Assignee
NUTRICION TECNICA DEPORTIVA S L
Nutricion Tecnica Deportiva Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49585441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2444299(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NUTRICION TECNICA DEPORTIVA S L, Nutricion Tecnica Deportiva Sl filed Critical NUTRICION TECNICA DEPORTIVA S L
Priority to ES201231324A priority Critical patent/ES2444299B1/es
Priority to PCT/IB2013/056775 priority patent/WO2014030125A2/en
Priority to AU2013307236A priority patent/AU2013307236B2/en
Priority to US14/422,951 priority patent/US9662369B2/en
Priority to MX2015002182A priority patent/MX357829B/es
Priority to CA2882790A priority patent/CA2882790C/en
Priority to PE2015000224A priority patent/PE20150558A1/es
Priority to SG11201501223QA priority patent/SG11201501223QA/en
Priority to EP13792072.4A priority patent/EP2887951B1/en
Priority to BR112015003828A priority patent/BR112015003828A2/pt
Priority to ES13792072.4T priority patent/ES2631927T3/es
Publication of ES2444299A1 publication Critical patent/ES2444299A1/es
Publication of ES2444299B1 publication Critical patent/ES2444299B1/es
Application granted granted Critical
Priority to CL2015000344A priority patent/CL2015000344A1/es
Priority to ZA2015/01071A priority patent/ZA201501071B/en
Priority to CR20150130A priority patent/CR20150130A/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

La presente invención se refiere al uso de un hidrolizado de caseína como agente antiherpético. Dicho hidrolizado de caseína tiene aplicación tanto en el tratamiento como en la prevención de la reactivación de una infección latente por un herpesvirus y presenta una eficacia tanto por vía oral como por vía tópica. También se refiere a una composición farmacéutica en forma de crema, gel, pomada o pasta para administración tópica que lo contiene.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
Hidrolizado de caseína
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14

Claims (1)

  1. imagen1
    imagen2
ES201231324A 2012-08-23 2012-08-23 Uso de un hidrolizado de caseina como agente antiherpético Expired - Fee Related ES2444299B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES201231324A ES2444299B1 (es) 2012-08-23 2012-08-23 Uso de un hidrolizado de caseina como agente antiherpético
EP13792072.4A EP2887951B1 (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
ES13792072.4T ES2631927T3 (es) 2012-08-23 2013-08-21 Uso de un hidrolizado de caseína como agente antiherpético
US14/422,951 US9662369B2 (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
MX2015002182A MX357829B (es) 2012-08-23 2013-08-21 Uso de un hidrolizado de caseína como agente antiherpético.
CA2882790A CA2882790C (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
PE2015000224A PE20150558A1 (es) 2012-08-23 2013-08-21 Uso de un hidrolizado de caseina como agente antiherpetico
SG11201501223QA SG11201501223QA (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
PCT/IB2013/056775 WO2014030125A2 (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
BR112015003828A BR112015003828A2 (pt) 2012-08-23 2013-08-21 uso de um hidrolisado de caseína como um agente anti-herpético
AU2013307236A AU2013307236B2 (en) 2012-08-23 2013-08-21 Use of a casein hydrolysate as an antiherpetic agent
CL2015000344A CL2015000344A1 (es) 2012-08-23 2015-02-13 Uso de un hidrolizado de caseina como agente antiherpético y composicion farmaceutica que comprende dicho hidrolizado.
ZA2015/01071A ZA201501071B (en) 2012-08-23 2015-02-16 Use of a casein hydrolysate as an antiherpetic agent
CR20150130A CR20150130A (es) 2012-08-23 2015-03-12 Uso de un hidrolizado de caseína como agente antiherpético

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231324A ES2444299B1 (es) 2012-08-23 2012-08-23 Uso de un hidrolizado de caseina como agente antiherpético

Publications (2)

Publication Number Publication Date
ES2444299A1 ES2444299A1 (es) 2014-02-24
ES2444299B1 true ES2444299B1 (es) 2014-12-12

Family

ID=49585441

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201231324A Expired - Fee Related ES2444299B1 (es) 2012-08-23 2012-08-23 Uso de un hidrolizado de caseina como agente antiherpético
ES13792072.4T Active ES2631927T3 (es) 2012-08-23 2013-08-21 Uso de un hidrolizado de caseína como agente antiherpético

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13792072.4T Active ES2631927T3 (es) 2012-08-23 2013-08-21 Uso de un hidrolizado de caseína como agente antiherpético

Country Status (13)

Country Link
US (1) US9662369B2 (es)
EP (1) EP2887951B1 (es)
AU (1) AU2013307236B2 (es)
BR (1) BR112015003828A2 (es)
CA (1) CA2882790C (es)
CL (1) CL2015000344A1 (es)
CR (1) CR20150130A (es)
ES (2) ES2444299B1 (es)
MX (1) MX357829B (es)
PE (1) PE20150558A1 (es)
SG (1) SG11201501223QA (es)
WO (1) WO2014030125A2 (es)
ZA (1) ZA201501071B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544153B1 (es) 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529880D0 (en) 1985-12-04 1986-01-15 Medical Res Council Polypeptide & pharmaceutical composition
US4795740A (en) 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
EP0292255A3 (en) 1987-05-22 1990-08-22 Merck & Co. Inc. Inhibitor of ribonucleotide reductase
US5120639A (en) 1989-04-03 1992-06-09 E. R. Squibb & Sons, Inc. Selective inhibition of dna polymerase
DE3922453A1 (de) 1989-07-07 1991-01-17 Gauri Kailash Kumar Pharmakologisch wirksame produkte aus molkeproteinhydrolysaten und verfahren zu deren gewinnung
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
WO1993021941A1 (en) 1992-04-23 1993-11-11 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5441936A (en) 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
GB9615730D0 (en) 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 1
ES2293977T3 (es) 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation Peptidos antivirales farmacologicamente activos y metodo para su uso.
AU3456102A (en) * 2000-12-07 2002-06-18 Dsm Nv Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
EP1568377A1 (en) * 2002-11-29 2005-08-31 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
ATE551048T1 (de) * 2004-06-28 2012-04-15 Dsm Ip Assets Bv Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EP1778271B1 (en) 2004-08-18 2008-10-22 IPF Pharmaceuticals GmbH Peptides for the treatment of herpes virus infections
US20090176743A1 (en) 2005-07-29 2009-07-09 Priscilla Schaffer Methods for treating or preventing reactivation of a latent herpesvirus infection
TW201000634A (en) * 2008-05-30 2010-01-01 Dsm Ip Assets Bv Proline-specific protease
US20090311236A1 (en) * 2008-06-11 2009-12-17 Immune @Work, Inc. Therapeutic Peptide Compositions And Methods Of Making And Using Same
WO2011138489A1 (es) * 2010-05-06 2011-11-10 Consejo Superior De Investigaciones Científicas (Csic) Uso de hidrolizados de caseínas como antivirales

Also Published As

Publication number Publication date
WO2014030125A2 (en) 2014-02-27
CA2882790A1 (en) 2014-02-27
EP2887951A2 (en) 2015-07-01
EP2887951B1 (en) 2017-04-05
AU2013307236B2 (en) 2016-11-17
AU2013307236A1 (en) 2015-03-05
MX357829B (es) 2018-07-25
ZA201501071B (en) 2016-01-27
CR20150130A (es) 2015-05-13
ES2631927T3 (es) 2017-09-06
US9662369B2 (en) 2017-05-30
US20150343010A1 (en) 2015-12-03
MX2015002182A (es) 2015-07-06
CL2015000344A1 (es) 2015-06-05
CA2882790C (en) 2017-07-04
PE20150558A1 (es) 2015-05-14
WO2014030125A3 (en) 2014-04-10
SG11201501223QA (en) 2015-03-30
BR112015003828A2 (pt) 2017-07-04
ES2444299A1 (es) 2014-02-24

Similar Documents

Publication Publication Date Title
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
SMT201400076B (it) Formulazioni farmaceutiche contro l'uso improprio di medicinali
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
AR088232A1 (es) Composiciones farmaceuticas
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes
CL2014003237A1 (es) Formulación farmacéutica estable que comprende un anticuerpo anti-dll4 (ligando tipo delta humano 4); y kit que comprende la composición en un envase e instrucciones.
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
CL2015000848A1 (es) Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12).
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
ES2544153B1 (es) Uso de un hidrolizado de caseína como agente antiviral
ES2444299B1 (es) Uso de un hidrolizado de caseina como agente antiherpético
BR112015030350A2 (pt) forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular
CL2014003361A1 (es) Profarmaco de ácido fosforamidico del compuesto 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida; composicion farmaceutica y uso en el tratamiento o la prevencion de la arritmia.
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt
JP2012097034A5 (es)
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2444299

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20141212

PC2A Transfer of patent

Owner name: NTD LABS, S.L.

Effective date: 20150522

FD2A Announcement of lapse in spain

Effective date: 20211230